Neovacs

Neovacs Dividend Coverage

Dividend Coverage Ratio of Neovacs (ALNEV.PA) as of Oct 16, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Neovacs is 2026 - . Dividend Coverage Ratio of Neovacs was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neovacs Stock analysis

What does Neovacs do? Neovacs SA is a biotechnology company headquartered in Paris, France, specializing in the development of active immunotherapies for autoimmune, inflammatory, and cancerous diseases. The firm employs 24 full-time staff and operates in France and the United States. Neovacs focuses on creating Kinoids, which are drug candidates designed to treat disease by inducing an antibody response in the patient. Its product portfolio includes TNF-Kinoids, IFN-Kinoids, and VEGF-Kinoids. The company specifically targets conditions such as Crohn’s disease, rheumatoid arthritis, and lupus. In May 2016, Neovacs entered into a joint venture agreement with Stellar Biotechnologies Inc to establish Neostell, in which Neovacs holds a 70% stake. The company listed on the market on April 15, 2010. Neovacs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neovacs stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Neovacs since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Neovacs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Neovacs

All Key Metrics — Neovacs